NCT05389527进行中（未招募）2 期
Efficacy and Safety of the Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients
Shanghai Zhongshan Hospital4 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2022年9月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
- 试验地点
- 4
- 主要终点
- Major pathological response (MPR)
研究概览
简要总结
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable hepatocellular carcinoma (HCC).
详细描述
The recurrence rate of hepatocellular carcinoma (HCC) after curative surgery is high and the survival benefit is limited. Neoadjuvant therapy, by targeting the disseminated tumor cells before curative surgery, may lower the incidence of tumor recurrence. In KEYNOTE-524 study, lenvatinib plus pembrolizumab combination showed promising efficacy and manageable toxicity. This study will evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable HCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically/cytologically or clinically (according to American Association for the Study of Liver Diseases (AASLD) criteria) confirmed diagnosis of HCC, excluding fibrolamellar sarcomatoid or mixed cholangiocarcinoma-hepatocellular carcinoma.
- •Have not received any locoregional or systemic treatment before enrolment. Patients had recurrence for more than 2 years after the previous surgery could be included.
- •Tumor within Milan criteria should be accompanied with microvascular invasion (judged by radionics nomogram of Fudan Zhongshan Hosp); Or beyond Milan criteria without extrahepatic metastasis.
- •Resectable disease as judged by a multidisciplinary treatment group.
- •Child-Pugh A.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1 and performed within 7 days prior to date of enrolment.
- •In case of hepatitis B virus (HBV) positive (HBsAg (+)) subjects:
- •HBV DNA < 2000 IU/mL within 28 days before treatment; subjects received anti-HBV therapy should stay on the same therapy throughout study treatment.
- •Subjects with HBV DNA > 2000 IU/mL without anti-HBV therapy, should receive anti-HBV therapy and stay the same therapy throughout study treatment, and 2 days before treatment, the HBV DNA should decrease for at least 1 log.
- •Subjects with HBV DNA > 2000 IU/mL with anti-HBV therapy, should receive anti-HBV therapy and stay the same therapy throughout study treatment, and 2 days before treatment, the HBV DNA should decrease at least 1 log.
- •Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to the treatment.
- •Have measurable disease based on RECIST 1.
- •Have adequate organ function. Specimens collected within 7 days prior to start of study treatment.
- •Male participants: A male participant must agree to use a contraception of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
- •Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- •The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
排除标准
- •Imaging findings for HCC of clear invasion into the bile duct or portal vein invasion with Vp
- •Positive pregnancy test in female patients with childbearing potential within 72 hours prior to enrollment.
- •Prior anticancer treatment or any investigational agent.
- •Subjects having ≥2+ proteinuria on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥1 g/24-hour will be ineligible.
- •Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
- •New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months.
- •Prolongation of corrected QT (QTc , Fridericia formula) interval to >480 ms.
- •Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
- •Bleeding or thrombotic disorders or use of factor X inhibitors or anticoagulants requiring therapeutic international normalized ratio (INR) monitoring, eg, warfarin or similar agents. Treatment with low molecular weight heparin is permitted. Antiplatelet agents are prohibited throughout the study.
- •Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
- •Subject is known to be positive for Human Immunodeficiency Virus (HIV).
- •Serious nonhealing wound, ulcer, or bone fracture.
- •History of solid organ or hematologic transplant.
- •Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
- •Active, known or suspected autoimmune disease that has required systemic treatment in the past 2 years or a documented history of clinically severe autoimmune disease, or any other syndrome that requires systemic steroids or immunosuppressive agents, patients with hypothyroidism stable on hormone replacement, or type 1 diabetes on insulin replacement will not be excluded from the study.
- •Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis or has a history of interstitial lung disease.
- •Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
研究组 & 干预措施
experimental arm
Experimental
Pembrolizumab+Lenvatinib
干预措施: Pembrolizumab+Lenvatinib (Drug)
结局指标
主要结局
Major pathological response (MPR)
时间窗: up to 24 weeks
Defined as ≤ 50% viable tumor cells pathologically in the resected specimen.
次要结局
- Pathologic complete response (pCR)(up to 24 weeks)
- Objective response rate (ORR)(up to 24 weeks)
- R0 resection rate(up to 24 weeks)
- Disease-free survival (DFS)(up to 2 years)
- 1-year DFS rate(up to 2 years)
- Overall survival(up to 2 years)
- Adverse event (AE)(up to 2 years)
研究者
Hui-Chuan Sun
Professor of Surgery
Shanghai Zhongshan Hospital
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerRecurrent Platinum Resistant Ovarian CancerNCT02889900AstraZeneca62
终止
2 期
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-IntronAdvanced CholangiocarcinomaNCT02982720Aiwu Ruth He, MD4
终止
2 期
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerOvarian NeoplasmsNCT03955471Tesaro, Inc.41
终止
2 期
Evaluation of Votrient in AngiosarcomaAngiosarcomaNCT02212015Heidelberg University26
已完成
2 期
Chemotherapy for Lung Cancer in HIV-positive PatientsHiv-positiveNon-small Cell Lung CancerNCT01296113Intergroupe Francophone de Cancerologie Thoracique61